Valeant buys contact lens firm Unilens Vision
Executive Summary
Valeant Pharmaceuticals International Inc. bought public contact lens firm Unilens Vision Inc. for $22.4mm in cash ($12.75 per share; a 24% premium) plus $5mm in debt.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice